Follow-up on HBsAg: According to the AASLD webcast, ASMB thinks HBsAg has little if any consequence as a predictor of a complete response (i.e. cure) to chronic HBV.
A cynic would say that this is a convenient position for ASMB to take insofar as ASMB’s lead CpAM, ABI-H0731, does a poor job of reducing HBsAg in comparison to other HBV biomarkers: #msg-151764106, #msg-152253534 (chase link in embedded tweet).
Nevertheless, I think ASMB’s thesis vis-à-vis HBsAg’s role makes a lot of sense scientifically. My problem with ASMB, from an investment standpoint, is not in regard to their ideas about how to treat/cure HBV, but rather is that ABI-H0731 is a weak compound (#msg-148672065) and the company’s follow-on candidate (ABI-H2158) is still an unknown in terms of efficacy.
(Moreover, I'm a skeptic regarding biotech companies who are working on the microbiome, which is ASMB's other area of focus.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.